Year archive

SynAct Pharma — 2024 filings

All 62 regulatory filings released by SynAct Pharma (SYNACT) in 2024, sourced directly from the official regulator.

62 Filings

2024 Period

2024 filings (62)

Filing	Released	Lang
Change in number of shares and votes in SynAct Pharma AB Share Issue/Capital Change	2024-12-30	English
Ändring av antalet aktier och röster i SynAct Pharma AB Declaration of Voting Results & Voting Rights Announcements	2024-12-30	Swedish
Major Shareholding Notification 2024 Major Shareholding Notification	2024-12-30	Swedish
Updated first day of trading in subscriptions rights Capital/Financing Update	2024-12-19	English
Uppdaterad första dag för handel i teckningsrätter Share Issue/Capital Change	2024-12-19	Swedish
Major Shareholding Notification 2024 Major Shareholding Notification	2024-12-19	Swedish
SynAct Pharma AB announces outcome of the directed share issues Capital/Financing Update	2024-12-17	English
SynAct Pharma AB offentliggör utfall av de riktade nyemissionerna av aktier Capital/Financing Update	2024-12-17	Swedish
SynAct Pharma AB offentliggör prospekt med anledning av upptagande till handel av nyemitterade aktier på Nasdaq Stockholm Report Publication Announcement	2024-12-17	Swedish
SynAct Pharma AB publishes prospectus in connection with admission to trading of new shares on Nasdaq Stockholm Report Publication Announcement	2024-12-17	English
Bulletin from the extraordinary general meeting of SynAct Pharma AB AGM Information	2024-12-13	English
Kommuniké från extra bolagsstämma i SynAct Pharma AB AGM Information	2024-12-13	Swedish
Nomination committee appointed ahead of AGM 2025 in SynAct Pharma AB AGM Information	2024-11-28	English
Valberedning utsedd inför årsstämma 2025 i SynAct Pharma AB AGM Information	2024-11-28	Swedish
Notice of extraordinary general meeting in SynAct Pharma AB AGM Information	2024-11-20	English
Kallelse till extra bolagsstämma i SynAct Pharma AB AGM Information	2024-11-20	Swedish
SynAct Pharma intends to carry out directed issues totalling approximately 45 MSEK and a fully guaranteed rights issue totalling approximately 20 MSEK Capital/Financing Update	2024-11-20	English
SynAct Pharma avser att genomföra riktade nyemissioner om totalt cirka 45 mkr och en fullt garanterad företrädesrättsemission om totalt cirka 20 mkr Share Issue/Capital Change	2024-11-20	Swedish
Interim / Quarterly Report 2024 Interim / Quarterly Report 9M 2024	2024-10-30	Swedish
Interim / Quarterly Report 2024 Interim / Quarterly Report 9M 2024	2024-10-30	English
Interim / Quarterly Report 2024 Interim / Quarterly Report H1 2024	2024-08-20	Swedish
Interim / Quarterly Report 2024 Interim / Quarterly Report Q2 2024	2024-08-20	English
Bulletin from the annual general meeting 2024 in SynAct Pharma AB AGM Information	2024-05-31	English
Kommuniké från årsstämma 2024 i SynAct Pharma AB AGM Information	2024-05-31	Swedish
Interim / Quarterly Report 2024 Interim / Quarterly Report Q1 2024	2024-05-31	Swedish
Interim / Quarterly Report 2024 Interim / Quarterly Report Q1 2024	2024-05-31	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-05-08	English
Major Shareholding Notification 2024 Major Shareholding Notification	2024-05-03	English
Ändring av antalet aktier och röster i SynAct Pharma AB Declaration of Voting Results & Voting Rights Announcements	2024-04-30	Swedish
Change in number of shares and votes in SynAct Pharma AB Declaration of Voting Results & Voting Rights Announcements	2024-04-30	English
Notice of annual general meeting in SynAct Pharma AB Proxy Solicitation & Information Statement	2024-04-30	English
Kallelse till årsstämma i SynAct Pharma AB Proxy Solicitation & Information Statement	2024-04-30	Swedish
Kommuniké från extra bolagsstämma i SynAct Pharma AB AGM Information	2024-04-24	Swedish
Bulletin from the extraordinary general meeting of SynAct Pharma AB AGM Information	2024-04-24	English
Changes in SynAct Pharma’s Nomination Committee ahead of the 2024 Annual General Meeting Board/Management Information	2024-04-23	English
Förändringar i SynAct Pharmas valberedning inför årsstämman 2024 AGM Information	2024-04-23	Swedish
Kallelse till extra bolagsstämma i SynAct Pharma AB AGM Information	2024-03-27	Swedish
Notice of extraordinary general meeting in SynAct Pharma AB AGM Information	2024-03-27	English
SynAct Pharma AB har framgångsrikt avslutat bookbuilding-förfarandet – riktade nyemissioner tillför bolaget totalt upp till 49,2 MSEK Share Issue/Capital Change	2024-03-27	Swedish
SynAct Pharma AB has successfully completed the bookbuilding procedure - directed issues provide the company with a total of up to 49.2 MSEK. Capital/Financing Update	2024-03-27	English
SynAct Pharma AB announces intention to carry out directed share issues in total of approximately 48 MSEK Capital/Financing Update	2024-03-26	English
SynAct Pharma AB offentliggör avsikt att genomföra riktade nyemissioner av aktier om totalt cirka 48 MSEK Capital/Financing Update	2024-03-26	Swedish
Annual Report (ESEF) 2023 Annual Report (ESEF) FY 2023	2024-03-26	Swedish
SynAct Pharma AB (publ) (”SynAct”) tidigarelägger publicering av årsredovisning. Report Publication Announcement	2024-03-25	Swedish
SynAct Pharma AB (publ) ("SynAct") brings forward the publication of the annual report. Report Publication Announcement	2024-03-25	English
Declaration of Voting Results & Voting Rights Announcements 2024 Declaration of Voting Results & Voting Rights Announcements	2024-03-20	English
SynAct Pharma appoints Jeppe Øvlesen CEO Board/Management Information	2024-03-20	English
SynAct Pharma utser Jeppe Øvlesen till VD Board/Management Information	2024-03-20	Swedish
Bulletin from the extraordinary general meeting of SynAct Pharma AB AGM Information	2024-03-20	English
Kommuniké från extra bolagsstämma i SynAct Pharma AB AGM Information	2024-03-20	Swedish
Major Shareholding Notification 2024 Major Shareholding Notification	2024-03-12	English
SynAct Pharma meddelar utfall av den oberoende granskningen av den kliniska 4 veckors-studien RESOLVE fas 2a i reumatoid artrit Legal Proceedings Report	2024-03-10	Swedish
SynAct Pharma announces outcomes of the independent audit of the 4-week RESOLVE P2a clinical trial in Rheumatoid Arthritis Legal Proceedings Report	2024-03-10	English
Marina Bozilenko avgår som styrelseledamot i SynAct Pharma Board/Management Information	2024-02-27	Swedish
Marina Bozilenko resigns from Board of Directors of SynAct Pharma Board/Management Information	2024-02-27	English
Interim / Quarterly Report 2023 Interim / Quarterly Report Q4 2023	2024-02-23	Swedish
Interim / Quarterly Report 2023 Interim / Quarterly Report Q4 2023	2024-02-23	English
Regulatory Filings 2024 Regulatory Filings	2024-02-23	English
Kallelse till extra bolagsstämma i SynAct Pharma AB AGM Information	2024-02-07	Swedish
Notice of extraordinary general meeting in SynAct Pharma AB AGM Information	2024-02-07	English
SynAct Pharma AB har mottagit begäran om att kalla till extra bolagsstämma AGM Information	2024-01-28	Swedish
The Board of Directors of SynAct Pharma AB has received a request to convene an EGM AGM Information	2024-01-28	English